You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

GSK Highlights from ATS

The IMPACT study (Informing the Pathway of COPD Treatment)

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/mp4/copd-video-recording-dave-lipson-pm-gb-ucv-wcnt-200019.mp4

Mortality data from the IMPACT study
Speaker Dr David A Lipson. GSK, Collegeville, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Find out more about IMPACT

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/mp4/copd-video-recording-dave-singh-pm-gb-fvu-vid-200014.mp4

Potential mechanisms of mortality reduction
Speaker Professor David Singh is Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, United Kingdom

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/mp4/copd-video-recording-neil-barnes-pm-gb-ucv-wcnt-200020.mp4

The molecules may explain the mortality benefit.
Speaker Professor Neil Barnes GSK, Brentford Middlesex, UK; Barts and the London School of Medicine and Dentistry, London, UK.

Find out more about the molecules

Other GSK clinical data from ATS

INTREPID: Investigation of Trelegy Effectiveness: Usual Practice Design

Assessing the effectiveness of Trelegy Ellipta relative to non-Ellipta multiple inhaler triple therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual clinical practice setting.
Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/mp4/ats-2020-scientific-poster-video-intrepid-pm-gb-fvu-vid-200016.mp4

Clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol versus multiple-inhaler triple therapy in usual clinical practice
Speaker Professor David Halpin is Consultant Physician and Honorary Associate Professor in Respiratory Medicine at the Royal Devon and Exeter Hospital, Exeter, UK

Find out more about INTREPID.

The EMAX trial: Early MAXimal bronchodilation for improving COPD stability

Comparing efficacy of Anoro Ellipta, with Incruse Ellipta and Serevent (salmeterol) in symptomatic low exacerbation risk patients with COPD not considered appropriate for ICS-containing therapy

Predicting improvements in COPD with clinically important improvements in patient reported outcomes: a post hoc analysis of the EMAX trial.
Speaker Professor Claus Vogelmeier, MD, Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany

Find out more about the EMAX trial.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Trelegy, Anoro, Relvar, Incruse, ELIPTA are registered trademark of the GlaxoSmithKline group of companies